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Background: The TRACER trial compared vorapaxar, a novel platelet PAR-1 antagonist, with placebo in 12944 patients with NSTE ACS. Vorapaxar 
nominally reduced myocardial infarction (MI). We explored this effect on different types and size of MI.
Methods: A central committee prospectively defined and classified MI according to universal MI types, biomarker infarct size (peak CK-MB/ULN 
ratio), ST-elevation, and Q-waves.
Results: During a median follow-up of 500 days, 1380 MIs occurred. Of these, 837 were type 1 (spontaneous; 60.7%), 349 were type 4a (peri-PCI; 
25.3%), 83 were type 4b (associated with stent thrombosis; 6%), 111 (8%) were of other universal MI type. Vorapaxar nominally reduced all MIs by 
12% (HR 0.88; 95% CI 0.79-0.98; P=0.021) compared with placebo, with a continuous effect over time. Vorapaxar nominally reduced spontaneous 
MI (HR 0.83; 95% CI 0.73-0.95; P=0.007). Peri-PCI MIs were numerically lower with vorapaxar (HR 0.90; 95% CI 0.73-1.12; P=0.3). The observed 
reduction with vorapaxar was similar across different infarct sizes (Figure). Type 4b MIs were similar between groups (42 vorapaxar, 41 placebo: 
HR 1.02 95% CI 0.66-1.57; P=0.9). STEMIs were numerically lower with vorapaxar (72, 1.1%) compared with placebo (81, 1.3%). QWMIs were 
infrequent and similar between the 2 groups (34 vorapaxar vs 36 placebo).
Conclusions: In patients with NSTE ACS, vorapaxar compared with placebo nominally reduced MI, an effect seen on both small and large MI, with 
a predominant reduction on spontaneous MI.
 
